Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study

Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was assessed in PATENT–CHILD (NCT02562235), a multicenter, singl...

Descripción completa

Detalles Bibliográficos
Autores principales: García Aguilar, Humberto, Gorenflo, Matthias, Ivy, D. Dunbar, Moledina, Shahin, Castaldi, Biagio, Ishida, Hidekazu, Cześniewicz, Paweł, Kusa, Jacek, Miera, Oliver, Pattathu, Joseph, Weng, Ken‐Pen, Ablonczy, Laszlo, Apitz, Christian, Katona, Marta, Kurosaki, Kenichi, Pulido, Tomas, Yamagishi, Hiroyuki, Yasuda, Kazushi, Cisternas, Galia, Goth, Melanie, Lippert, Susanne, Radomskyj, Anna, Saleh, Soundos, Willmann, Stefan, Wirsching, Gabriela, Bonnet, Damien, Beghetti, Maurice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485817/
https://www.ncbi.nlm.nih.gov/pubmed/36186721
http://dx.doi.org/10.1002/pul2.12133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485817/
https://www.ncbi.nlm.nih.gov/pubmed/36186721
http://dx.doi.org/10.1002/pul2.12133

Ejemplares similares